GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Equity-to-Asset

Adial Pharmaceuticals (Adial Pharmaceuticals) Equity-to-Asset

: 0.86 (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Adial Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4.08 Mil. Adial Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $4.74 Mil.

The historical rank and industry rank for Adial Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

ADIL' s Equity-to-Asset Range Over the Past 10 Years
Min: -28.51   Med: 0.73   Max: 0.95
Current: 0.86

During the past 9 years, the highest Equity to Asset Ratio of Adial Pharmaceuticals was 0.95. The lowest was -28.51. And the median was 0.73.

ADIL's Equity-to-Asset is ranked better than
77.97% of 1566 companies
in the Biotechnology industry
Industry Median: 0.67 vs ADIL: 0.86

Adial Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Adial Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.73 0.47 0.57 0.86

Adial Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.37 0.88 0.82 0.86

Competitive Comparison

For the Biotechnology subindustry, Adial Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adial Pharmaceuticals Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Adial Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Adial Pharmaceuticals's Equity-to-Asset falls into.



Adial Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Adial Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=4.084/4.737
=

Adial Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=4.084/4.737
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adial Pharmaceuticals  (NAS:ADIL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Adial Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Adial Pharmaceuticals (Adial Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1180 Seminole Trail, Suite 495, Charlottesville, VA, USA, 22901
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.
Executives
Kevin Schuyler director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii director, 10 percent owner, officer: Chief Executive Officer 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr. director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson director, 10 percent owner 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich director C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck officer: COO and CFO 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust 10 percent owner 11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042

Adial Pharmaceuticals (Adial Pharmaceuticals) Headlines